Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12618001958279
ACTRN12618001958279
Not yet recruiting
Phase 2

Defining the Novel Effects of Mineralocorticoid Receptor Antagonism on Metabolism in Humans – A Randomised Controlled Trial

Dr Moe Thuzar0 sites32 target enrollmentDecember 4, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsObesityMetabolic and Endocrine - Metabolic disordersDiet and Nutrition - Obesity

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Obesity
Sponsor
Dr Moe Thuzar
Enrollment
32
Status
Not yet recruiting
Last Updated
7 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 4, 2018
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Dr Moe Thuzar

Eligibility Criteria

Inclusion Criteria

  • •BMI 25\-40 kg/m2

Exclusion Criteria

  • •(i) estimated glomerular filtration rate (eGFR) less than 60 ml/min
  • •(ii) serum potassium more than 5mmol/L in a non\-haemolysed blood sample
  • •(iii) thyroid or endocrine dysfunction
  • •(iv) significant organ dysfunction such as heart failure, liver failure
  • •(v) active malignancy
  • •(vi) pregnant or planning pregnancy
  • •(vii) unable to provide informed consent
  • •(viii) alcohol intake \>14 standard drinks per week or smoking
  • •(ix) Unable to maintain stable diet and lifestyle during the study period
  • •(x) taking medications that may interact with spironolactone or have effect on metabolism such as anti\-hypertensives acting on the renin\-angiotensin or sympathetic system, diuretics, anti\-diabetic medications, corticosteroids, anti\-psychotics

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Effects of eplerenone on forearm blood flowhealthy volunteersTherapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]
EUCTR2013-000189-12-NLniversity Medical Centre Nijmegen
Completed
Not Applicable
Effects of the selective mineralocorticoid receptor antagonist eplerenone on extracellular adenosine formation in humans in vivoblood flowischemia reperfusion injury10011082
NL-OMON38928niversitair Medisch Centrum Sint Radboud14
Completed
Phase 2
Effects of mineralocorticoid receptor agonist on intradialytic hypotension: an open-label, randomized crossover studyIntradialytic hypotensionMineralocorticoid receptor agonist
TCTR20200128004ampang hospital10
Completed
Phase 2
Effects of mineralocorticoid receptor antagonist on intradialytic hypertension: a multicenter, double-blind, randomized crossover studyIntradialytic hypertensionSpironolactoneMineralocorticoid receptor antagonist
TCTR20200604013ampang hospital49
Completed
Not Applicable
Effects of mineralocorticoid receptor antagonists on sex hormones and body composition in patients with primary aldosteronismPrimary aldosteronism
JPRN-UMIN000037657Tokyo Women's Medical University Hospital100